In the world of optometry and ophthalmology, staying at the forefront of patient care and treatment options is paramount. Dry Eye Disease (DED) is a common yet frustrating condition that affects a significant portion of the population. The good news is that there’s a groundbreaking solution – OptiLIGHT, the first and only FDA-approved light-based therapy for dry eye management. Supported by over 20 clinical studies, OptiLIGHT offers a precise, controlled, and effective approach to DED treatment, promising to transform your practice and elevate the care you provide.
The Dry Eye Epidemic in Canada
In Canada, dry eye is far from a rare condition. It’s estimated that approximately 30% of Canadians experience ocular symptoms associated with DED. At the average eye care center, a staggering 70 patients walk through the door every week, and a significant 21 of them are battling dry eyes. What’s intriguing is that one-third of these patients opt for OptiLIGHT as their chosen treatment. With an estimated ROI within just 4-6 months after treating 40 patients, the prospects are undeniably promising.
Dr. Higgins’ Success Story
Dr. Higgins, like many of his peers, was no stranger to treating dry eye disease. He had employed the “usual” treatments such as Restasis, Lotemax, and punctal plugs, yet often found himself unsatisfied with the outcomes. Recognizing the unmet needs in serving the dry eye population and aiming to take his practice to the next level, Dr. Higgins made the pivotal decision to acquire an OptiLIGHT device.
Over the course of a year and a half, the practice witnessed remarkable growth, achieving a 50% increase in patient care. They became known as a “referral center,” seeing patients referred to them by fellow optometrists, ophthalmologists, dermatologists, and rheumatologists. Their dedication to elevating the practice didn’t stop there. Effective marketing and SEO by Marketing4ECPs positioned them at the top of Google searches for dry eye disease and treatment-related keywords. With over 10 new referrals each week from fellow professionals and an email open rate averaging 38%, Dr. Higgins’ practice proved that embracing OptiLIGHT and effective marketing strategies could create an outstanding success story.
OptiLIGHT – A Game-Changer for Practice Growth
But what exactly is OptiLIGHT, and why is it such a game-changer? It’s a non-invasive, drug-free treatment method that operates on patented Optimal Pulse Technology (OPT™). The beauty of OptiLIGHT is not only in its effectiveness but also in its efficiency. Each treatment session takes just 15 minutes, making it seamlessly integrated into your practice.
Laura M. Periman, MD, a “Dry Eye Master,” has this to say about the ease of integration, “Each treatment takes 15 minutes in total, which has made it easy to efficiently integrate into the practice. I now perform about 20 OptiLIGHT procedures each week. My patients are very happy with the results, and they appreciate the convenience of having an in-office procedure.”
Serving Both Optometrists and Ophthalmologists
OptiLIGHT isn’t limited to one specific realm of eye care. It’s a valuable tool for both optometrists and ophthalmologists, enhancing their capabilities and patient offerings. Its multifactorial approach addresses the complexity of DED, making it an essential addition to the arsenal of professionals in both fields.
Expanding Revenue Streams
Moreover, OptiLIGHT doesn’t just address DED; it opens doors to new revenue streams. Surgeries like cataracts and LASIK can trigger or worsen dry eye symptoms. Clinical studies indicate that around 48% of patients experience dry eye symptoms six months post-LASIK surgery. With OptiLIGHT, practices can expand into offering aesthetic treatments, thereby creating a lucrative revenue stream. Kickstart your new offering with this tax credit, available until December 31, 2023.
Availability and Conclusion
For those considering OptiLIGHT, it’s important to note that it’s available exclusively through Lumenis and is accessible not only in the United States but also now in Canada.
In conclusion, OptiLIGHT represents a remarkable breakthrough in the field of optometry and ophthalmology. With a staggering demand for DED treatments and the potential to significantly elevate patient care and practice revenue, there’s never been a better time to introduce OptiLIGHT into your practice. The success of Dr. Higgins, the multitude of clinical studies, and the ease of integration make OptiLIGHT a transformative force in the industry. Embrace this opportunity and revolutionize your practice today. Contact Lumenis to get started.